MCID: CHL065
MIFTS: 63

Cholangiocarcinoma

Categories: Liver diseases, Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Cholangiocarcinoma

MalaCards integrated aliases for Cholangiocarcinoma:

Name: Cholangiocarcinoma 57 38 12 76 25 59 37 55 15 73
Adult Primary Cholangiocellular Carcinoma 12 73
Cholangiocarcinoma, Susceptibility to 57 29
Intrahepatic Cholangiocarcinoma 25 73
Extrahepatic Cholangiocarcinoma 25 73
Cholangiocarcinoma of Biliary Tract 25
Adult Primary Cholangiocarcinoma 12
Cholangiocellular Carcinoma 25
Chlc, Susceptibility to 57
Bile Duct Carcinoma 73
Cholangiosarcoma 12
Bile Duct Cancer 59
Chlc 57
Cca 59
Cc 25

Characteristics:

Orphanet epidemiological data:

59
cholangiocarcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare hepatic diseases


External Ids:

OMIM 57 615619
Disease Ontology 12 DOID:4947
ICD10 33 C22.1
MeSH 44 D018281
NCIt 50 C4436 C8265
SNOMED-CT 68 312104005 70179006
Orphanet 59 ORPHA70567
ICD10 via Orphanet 34 C24.8 C24.9 C22.1 more
MESH via Orphanet 45 D001650 D018281
UMLS via Orphanet 74 C0206698 C0740277
MedGen 42 C3810156
KEGG 37 H00046

Summaries for Cholangiocarcinoma

OMIM : 57 Carcinomas of the biliary tract are aggressive malignancies, with 5-year survival of less than 10%. These carcinomas arise throughout the biliary tree and are anatomically classified as either intrahepatic or extrahepatic cholangiocarcinomas. Gallbladder carcinomas also arise from the biliary tree but have distinct natural histories compared to cholangiocarcinomas, suggesting different underlying tumor biology. Cholangiocarcinoma incidence varies widely between geographic regions, reflecting the impact of different underlying etiologies. In endemic areas, liver fluke infections by O. viverrini and Clonorchis sinensis, both group I carcinogens, represent the major risk factor for cholangiocarcinomas. In nonendemic regions, other risk factors, including choledochal cysts (603003), hepatolithiasis, and primary sclerosing cholangitis (613806), are likely contributors (summary by Chan-on et al., 2013). Overall, the majority of patients lack such identifiable risk factors (summary by Jiao et al., 2013). (615619)

MalaCards based summary : Cholangiocarcinoma, also known as adult primary cholangiocellular carcinoma, is related to klatskin's tumor and gallbladder cancer, and has symptoms including abdominal pain, malaise and constipation. An important gene associated with Cholangiocarcinoma is PTPN3 (Protein Tyrosine Phosphatase, Non-Receptor Type 3), and among its related pathways/superpathways is MicroRNAs in cancer. The drugs Sevoflurane and Isoflurane have been mentioned in the context of this disorder. Affiliated tissues include liver, small intestine and lymph node, and related phenotypes are jaundice and pruritus

Genetics Home Reference : 25 Cholangiocarcinoma is a group of cancers that begin in the bile ducts. Bile ducts are branched tubes that connect the liver and gallbladder to the small intestine. They carry bile, which is a fluid that helps the body digest the fats in food. Bile is produced in the liver and stored in the gallbladder before being released in the small intestine after a person eats.

Disease Ontology : 12 A bile duct adenocarcinoma that has material basis in bile duct epithelial cells.

Wikipedia : 76 Cholangiocarcinoma, also known as bile duct cancer, is a form of cancer that is composed of mutated... more...

Related Diseases for Cholangiocarcinoma

Diseases related to Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 218)
# Related Disease Score Top Affiliating Genes
1 klatskin's tumor 34.1 MALAT1 MIR373
2 gallbladder cancer 30.4 AFAP1-AS1 H19 MALAT1 TUG1
3 dermatomyositis 30.1 MIR148A MIR21
4 pancreatic ductal adenocarcinoma 30.0 AFAP1-AS1 H19 MALAT1 MIR141 MIR148A MIR21
5 melanoma 29.6 H19 MALAT1 MIR141 MIR200B MIR204 SOX2-OT
6 renal cell carcinoma, nonpapillary 29.4 H19 MALAT1 MIR141 PANDAR TUG1
7 glioblastoma 29.2 H19 MALAT1 MIR21 PCAT1 TUG1
8 pancreatic cancer 28.5 AFAP1-AS1 H19 HULC MALAT1 MIR148A MIR21
9 squamous cell carcinoma 28.1 CCAT2 H19 MALAT1 NEAT1 PCAT1 SOX2-OT
10 lung squamous cell carcinoma 28.0 CCAT2 SOX2-OT TUG1
11 hepatocellular carcinoma 27.1 AFAP1-AS1 CCAT2 H19 HULC MALAT1 MIR141
12 gastric cancer 27.1 AFAP1-AS1 CCAT2 H19 HULC MALAT1 MIR141
13 colorectal cancer 26.5 AFAP1-AS1 CCAT2 H19 HULC MALAT1 MIR141
14 breast cancer 25.7 CCAT2 H19 MALAT1 MIR141 MIR148A MIR152
15 intrahepatic cholangiocarcinoma 12.5
16 hilar cholangiocellular carcinoma 12.2
17 arthrogryposis, distal, type 9 12.1
18 mucinous intrahepatic cholangiocarcinoma 12.1
19 sarcomatous intrahepatic cholangiocarcinoma 12.1
20 signet ring cell intrahepatic cholangiocarcinoma 11.9
21 clonorchiasis 11.4
22 epilepsy occipital calcifications 11.4
23 cholangitis, primary sclerosing 11.3
24 opisthorchiasis 11.3
25 bile duct carcinoma 11.2
26 acrocallosal syndrome 11.1
27 familial calcium pyrophosphate deposition 11.1
28 central cord syndrome 11.1
29 ovarian serous carcinoma 11.0 MIR141 MIR21
30 congenitally corrected transposition of the great arteries 10.9
31 biliary tract neoplasm 10.9
32 endometriosis 10.8 H19 MIR141 MIR200B
33 tongue squamous cell carcinoma 10.8 AFAP1-AS1 MALAT1 MIR21
34 astrocytoma 10.7 H19 MIR21 NEAT1 SOX2-OT
35 esophagus adenocarcinoma 10.7 AFAP1-AS1 MIR21
36 prostate disease 10.7 H19 MALAT1 PCAT1
37 kidney cancer 10.7 H19 MALAT1 MIR141 MIR200B MIR21
38 hepatitis 10.6
39 malignant glioma 10.5 H19 MALAT1
40 cholangitis 10.5
41 squamous cell carcinoma, head and neck 10.5 H19 MIR141 MIR148A MIR204 MIR21 MIR373
42 sclerosing cholangitis 10.5
43 thyroid cancer, nonmedullary, 1 10.5 H19 HULC MALAT1 MIR21 NEAT1
44 esophagus squamous cell carcinoma 10.5 AFAP1-AS1 TUG1
45 diffuse large b-cell lymphoma 10.4 HULC MIR21 MIR320A PANDAR
46 pituitary adenoma 10.4 CCAT2 H19 MALAT1
47 nasopharyngeal carcinoma 10.3 AFAP1-AS1 H19 HULC MALAT1 NEAT1
48 thyroid cancer 10.2 AFAP1-AS1 H19 MALAT1 NEAT1 PANDAR
49 hepatitis b 10.2
50 ovarian epithelial cancer 10.2 CCAT2 H19 HULC MALAT1

Graphical network of the top 20 diseases related to Cholangiocarcinoma:



Diseases related to Cholangiocarcinoma

Symptoms & Phenotypes for Cholangiocarcinoma

Clinical features from OMIM:

615619

Human phenotypes related to Cholangiocarcinoma:

59 32 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 jaundice 59 32 hallmark (90%) Very frequent (99-80%) HP:0000952
2 pruritus 59 32 frequent (33%) Frequent (79-30%) HP:0000989
3 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
4 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
5 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
6 acholic stools 59 32 hallmark (90%) Very frequent (99-80%) HP:0011985
7 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
8 biliary tract neoplasm 59 32 hallmark (90%) Very frequent (99-80%) HP:0100574
9 cholangiocarcinoma 32 HP:0030153

UMLS symptoms related to Cholangiocarcinoma:


abdominal pain, malaise, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

Drugs & Therapeutics for Cholangiocarcinoma

Drugs for Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 295)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
2
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
3
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
4
Desflurane Approved Phase 4 57041-67-5 42113
5
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable 53608-75-6
6
Etomidate Approved Phase 4 33125-97-2 36339 667484
7
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
8
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
9
Meperidine Approved Phase 4 57-42-1 4058
10 pancreatin Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
11
Bismuth Phase 4,Phase 3 7440-69-9 16682734 105143
12
Bilirubin Phase 4,Not Applicable 635-65-4 5280352
13 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
14 Central Nervous System Depressants Phase 4,Phase 3,Not Applicable
15 GABA Agents Phase 4,Not Applicable
16 GABA Modulators Phase 4,Not Applicable
17 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
20 Anesthetics Phase 4,Phase 3
21 Anesthetics, General Phase 4,Phase 3
22 Anesthetics, Inhalation Phase 4
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Hypnotics and Sedatives Phase 4,Not Applicable
25 Platelet Aggregation Inhibitors Phase 4
26 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 1,Phase 2
29 Antirheumatic Agents Phase 4,Phase 1,Phase 2
30 Adjuvants, Anesthesia Phase 4,Phase 3
31 Narcotics Phase 4,Phase 3
32 Cyclooxygenase 2 Inhibitors Phase 4
33 Cyclooxygenase Inhibitors Phase 4
34 Analgesics, Opioid Phase 4,Phase 3
35 Anesthetics, Intravenous Phase 4,Phase 3
36 Tranquilizing Agents Phase 4,Phase 3
37 Anti-Anxiety Agents Phase 4,Phase 3
38 Psychotropic Drugs Phase 4,Phase 3
39 arginine Nutraceutical Phase 4
40 Cola Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 Omega 3 Fatty Acid Nutraceutical Phase 4
42
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
43
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
44
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
45
Fluorouracil Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 51-21-8 3385
46
Trioxsalen Approved Phase 2, Phase 3,Phase 3,Not Applicable 3902-71-4 5585
47
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 68538-85-2
48
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
49
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
50
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401

Interventional clinical trials:

(show top 50) (show all 453)
# Name Status NCT ID Phase Drugs
1 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent Unknown status NCT00746538 Phase 4
2 Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma Unknown status NCT00797121 Phase 4
3 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
4 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
5 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
6 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
7 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma Completed NCT00721175 Phase 4
8 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
9 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
10 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
11 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
12 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
13 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Enrolling by invitation NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
14 Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma Unknown status NCT02108145 Phase 2, Phase 3
15 Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
16 Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures Unknown status NCT00653978 Phase 3
17 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
18 S-1 and Photodynamic Therapy in Cholangiocarcinoma Completed NCT00869635 Phase 3 S-1 Chemotherapy
19 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
20 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3 porfimer sodium
21 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
22 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
23 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
24 Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
25 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
26 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
27 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
28 Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma Recruiting NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
29 Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma Recruiting NCT02773485 Phase 3 Systemic chemotherapy
30 SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
31 Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) Recruiting NCT02989857 Phase 3 AG-120;AG-120 matched placebo
32 Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
33 A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03251443 Phase 3 Apatinib
34 Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma Recruiting NCT01755013 Phase 2, Phase 3
35 Bortezomib in Intrahepatic Cholangiocellular Carcinoma Recruiting NCT03345303 Phase 3 Bortezomib
36 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
37 Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery Recruiting NCT02200042 Phase 3 Cisplatin;Gemcitabine Hydrochloride
38 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Recruiting NCT02798510 Phase 3 capecitabine;gemcitabine
39 Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
40 Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Recruiting NCT01470443 Phase 3 Oxaliplatin;Oxaliplatin
41 Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Recruiting NCT02853474 Phase 3
42 Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L Recruiting NCT02232490 Phase 3
43 Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Active, not recruiting NCT02482454 Phase 2, Phase 3
44 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
45 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Active, not recruiting NCT02349412 Phase 3
46 Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) Terminated NCT02082522 Phase 3 Photodynamic therapy-Photofrin;Chemotherapy regimen
47 Photodynamic Therapy (PDT) Trial for Palliation of Cholangiocarcinoma Terminated NCT00907413 Phase 3
48 Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas Terminated NCT00540735 Phase 3
49 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
50 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo

Search NIH Clinical Center for Cholangiocarcinoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cholangiocarcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Cholangiocarcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Cholangiocarcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Genetic Tests for Cholangiocarcinoma

Genetic tests related to Cholangiocarcinoma:

# Genetic test Affiliating Genes
1 Cholangiocarcinoma, Susceptibility to 29

Anatomical Context for Cholangiocarcinoma

MalaCards organs/tissues related to Cholangiocarcinoma:

41
Liver, Small Intestine, Lymph Node, Lung, Pancreas, Breast, Colon

Publications for Cholangiocarcinoma

Articles related to Cholangiocarcinoma:

(show top 50) (show all 2367)
# Title Authors Year
1
Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of I^-Catenin. ( 29415992 )
2018
2
Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system. ( 29434290 )
2018
3
Sirtuin7 has an oncogenic potential via promoting the growth of cholangiocarcinoma cells. ( 29438839 )
2018
4
MicroRNA-26b-5p regulates cell proliferation, invasion and metastasis in human intrahepatic cholangiocarcinoma by targeting S100A7. ( 29387225 )
2018
5
Enhanced expression of lncRNA TP73-AS1 predicts adverse phenotypes for cholangiocarcinoma and exerts oncogenic properties in vitro and in vivo. ( 29966969 )
2018
6
An interesting case of inflammatory myofibroblastic tumor presenting as cholangiocarcinoma. ( 29705678 )
2018
7
Characterization and prognostic significance of mortalin, Bcl-2 and Bax in intrahepatic cholangiocarcinoma. ( 29434920 )
2018
8
Opisthorchiasis-Induced Cholangiocarcinoma: How Innate Immunity May Cause Cancer. ( 29907253 )
2018
9
Challenges of surgical management of intrahepatic cholangiocarcinoma. ( 29911912 )
2018
10
Let-7c inhibits cholangiocarcinoma growth but promotes tumor cell invasion and growth at extrahepatic sites. ( 29445149 )
2018
11
Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. ( 29251327 )
2018
12
Impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma: a meta-analysis. ( 29947010 )
2018
13
Salinomycin inhibits cholangiocarcinoma growth by inhibition of autophagic flux. ( 29423070 )
2018
14
Thermal ablation of intrahepatic cholangiocarcinoma: Safety, efficacy, and factors affecting local tumor progression. ( 29869103 )
2018
15
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. ( 29874985 )
2018
16
Role of palliative radiotherapy in unresectable intrahepatic cholangiocarcinoma: population-based analysis with propensity score matching. ( 29942151 )
2018
17
Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing. ( 29976634 )
2018
18
Fyn knockdown inhibits migration and invasion in cholangiocarcinoma through the activated AMPK/mTOR signaling pathway. ( 29434909 )
2018
19
Role of fluorescence in situ hybridization in diagnosing cholangiocarcinoma in indeterminate biliary strictures. ( 28543841 )
2018
20
Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. ( 29887261 )
2018
21
Differential diagnosis of cholangiocarcinoma and IgG4-related sclerosing cholangitis by fluorescence inA situ hybridization using transpapillary forceps biopsy specimens. ( 29532638 )
2018
22
Unique Responses of Hepatocellular Carcinoma and Cholangiocarcinoma Cell Lines toward Cantharidin and Norcantharidin. ( 29937938 )
2018
23
Tumor-associated macrophages recruited by periostin in intrahepatic cholangiocarcinoma stem cells. ( 29805605 )
2018
24
Small intestinal obstruction due to the metastasis of intrahepatic cholangiocarcinoma: A case report. ( 29561438 )
2018
25
Preoperative Biliary Drainage Is Associated with Increased Complications After Liver Resection for Proximal Cholangiocarcinoma. ( 29980975 )
2018
26
<sup>18</sup>F-FDG PET/CT may be a suitable method for preoperative diagnosis and evaluation of Chinese older patients with hilar cholangiocarcinoma. ( 29976141 )
2018
27
<i>In Vivo</i> Study of Natural Killer (NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude Mouse Model. ( 29936458 )
2018
28
<sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Imaging of Inferior Vena Cava Tumor Thrombus Extending into the Right Atrium in a Patient with Cholangiocarcinoma Treated with <sup>90</sup>Y-Microspheres. ( 29962728 )
2018
29
Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. ( 29935812 )
2018
30
Prognostic comparison of the 7th and 8th editions of the American Joint Commission on Cancer staging system for intrahepatic cholangiocarcinoma. ( 29450978 )
2018
31
A novel prognostic biomarker for cholangiocarcinoma: circRNA Cdr1as. ( 29424892 )
2018
32
Potential role of HIF-1-responsive microRNA210/HIF3 axis on gemcitabine resistance in cholangiocarcinoma cells. ( 29953500 )
2018
33
RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis. ( 29913454 )
2018
34
Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. ( 29781738 )
2018
35
Upregulation of long nona89coding RNA CCAT2 indicates a poor prognosis and promotes proliferation and metastasis in intrahepatic cholangiocarcinoma. ( 29393466 )
2018
36
The expression and clinicopathological role of CDX2 in intrahepatic cholangiocarcinoma. ( 29862152 )
2018
37
Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. ( 29963132 )
2018
38
B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma. ( 29696716 )
2018
39
Current Perspectives on Opisthorchiasis Control and Cholangiocarcinoma Detection in Southeast Asia. ( 29765958 )
2018
40
The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma. ( 29438681 )
2018
41
Inhibition of IL-10 and TGF-I^ receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells. ( 29420117 )
2018
42
Inflammatory Myofibroblastic Tumor of the Mid Common Bile Duct Masquerading as Cholangiocarcinoma. ( 29453762 )
2018
43
Phenformin inhibits cell proliferation and induces cell apoptosis and autophagy in cholangiocarcinoma. ( 29436644 )
2018
44
Analysis of a school-based health education model to prevent opisthorchiasis and cholangiocarcinoma in primary school children in northeast Thailand. ( 29809091 )
2018
45
Comparison of the sixth and the seventh editions of the UICC classification for intrahepatic cholangiocarcinoma. ( 29859128 )
2018
46
Salubrinal Enhances Doxorubicin Sensitivity in Human Cholangiocarcinoma Cells Through Promoting DNA Damage. ( 29957018 )
2018
47
Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System. ( 28424987 )
2018
48
Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma. ( 29805522 )
2018
49
Towards Personalized Medicine for Intrahepatic Cholangiocarcinoma: Pharmacogenomic Stratification of Patients. ( 29394502 )
2018
50
DJ-1 is a useful biomarker for invasive extrahepatic cholangiocarcinoma. ( 29447925 )
2018

Variations for Cholangiocarcinoma

Cosmic variations for Cholangiocarcinoma:

9
(show top 50) (show all 2160)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6974042 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.6964C>T p.R2322* 16:72795718-72795718 13
2 COSM6957143 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.3529+1G>A p.? 16:72829778-72829778 13
3 COSM6928728 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 13
4 COSM6986174 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.273G>T p.W91C 2:61522639-61522639 13
5 COSM6975271 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.729G>T p.E243D 2:61498703-61498703 13
6 COSM6985358 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.338C>T p.T113M 2:61502274-61502274 13
7 COSM6923580 TSC1 biliary tract,bile duct,carcinoma,adenocarcinoma c.2551C>T p.Q851* 9:132900789-132900789 13
8 COSM4172016 TSC1 biliary tract,bile duct,carcinoma,adenocarcinoma c.737+1G>A p.? 9:132921362-132921362 13
9 COSM308173 TRIM28 biliary tract,bile duct,carcinoma,adenocarcinoma c.1475G>T p.R492L 19:58549053-58549053 13
10 COSM44463 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.848G>T p.R283L 17:7673772-7673772 13
11 COSM43687 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.641A>G p.H214R 17:7674890-7674890 13
12 COSM10687 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.527G>A p.C176Y 17:7675085-7675085 13
13 COSM10731 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.707A>G p.Y236C 17:7674256-7674256 13
14 COSM10662 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.743G>A p.R248Q 17:7674220-7674220 13
15 COSM10722 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.853G>A p.E285K 17:7673767-7673767 13
16 COSM43778 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.713G>T p.C238F 17:7674250-7674250 13
17 COSM44426 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.568C>G p.P190A 17:7674963-7674963 13
18 COSM44309 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.440T>G p.V147G 17:7675172-7675172 13
19 COSM43751 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.673-1G>A p.? 17:7674291-7674291 13
20 COSM43635 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.536A>T p.H179L 17:7675076-7675076 13
21 COSM22908 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.376-1G>T p.? 17:7675237-7675237 13
22 COSM44143 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.919+1G>A p.? 17:7673700-7673700 13
23 COSM10727 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.438G>A p.W146* 17:7675174-7675174 13
24 COSM44786 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.694A>C p.I232L 17:7674269-7674269 13
25 COSM10660 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.818G>A p.R273H 17:7673802-7673802 13
26 COSM43596 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.841G>A p.D281N 17:7673779-7673779 13
27 COSM10690 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.473G>A p.R158H 17:7675139-7675139 13
28 COSM11071 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.1009C>T p.R337C 17:7670700-7670700 13
29 COSM10749 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.830G>T p.C277F 17:7673790-7673790 13
30 COSM44262 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.808T>C p.F270L 17:7673812-7673812 13
31 COSM11078 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.1027G>T p.E343* 17:7670682-7670682 13
32 COSM10883 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.731G>A p.G244D 17:7674232-7674232 13
33 COSM44523 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.863A>G p.N288S 17:7673757-7673757 13
34 COSM10672 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.577C>T p.H193Y 17:7674954-7674954 13
35 COSM11355 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.737T>C p.M246T 17:7674226-7674226 13
36 COSM44226 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.380C>T p.S127F 17:7675232-7675232 13
37 COSM10725 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.701A>G p.Y234C 17:7674262-7674262 13
38 COSM10893 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.824G>A p.C275Y 17:7673796-7673796 13
39 COSM45025 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.488A>C p.Y163S 17:7675124-7675124 13
40 COSM6918 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.993+1G>T p.? 17:7673534-7673534 13
41 COSM44623 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.487T>A p.Y163N 17:7675125-7675125 13
42 COSM44271 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.688A>C p.T230P 17:7674275-7674275 13
43 COSM44215 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.533A>C p.H178P 17:7675079-7675079 13
44 COSM10742 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.578A>G p.H193R 17:7674953-7674953 13
45 COSM43909 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.817C>A p.R273S 17:7673803-7673803 13
46 COSM45393 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.793C>A p.L265M 17:7673827-7673827 13
47 COSM11552 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.775G>T p.D259Y 17:7674188-7674188 13
48 COSM44329 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.470T>A p.V157D 17:7675142-7675142 13
49 COSM10812 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.722C>T p.S241F 17:7674241-7674241 13
50 COSM11508 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.497C>A p.S166* 17:7675115-7675115 13

Copy number variations for Cholangiocarcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 111150 17 35097918 35138441 Copy number ERBB2 Cholangiocarcinoma
2 118016 17 7512444 7519279 Copy number P53 Cholangiocarcinoma
3 159441 21 42600000 48129895 Amplification TFF1 Cholangiocarcinoma
4 159442 21 42600000 48129895 Amplification TFF2 Cholangiocarcinoma
5 159443 21 42600000 48129895 Amplification TFF3 Cholangiocarcinoma

Expression for Cholangiocarcinoma

Search GEO for disease gene expression data for Cholangiocarcinoma.

Pathways for Cholangiocarcinoma

Pathways related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.5 MIR141 MIR152 MIR200B MIR21 MIR373

GO Terms for Cholangiocarcinoma

Cellular components related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 MIR141 MIR148A MIR152 MIR204 MIR21 MIR320A

Biological processes related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.17 MIR141 MIR148A MIR152 MIR200B MIR204 MIR21
2 negative regulation of blood vessel endothelial cell migration GO:0043537 9.13 MIR152 MIR200B MIR204

Molecular functions related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR141 MIR148A MIR152 MIR200B MIR204 MIR21

Sources for Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....